三重组合的DBDx减轻了细胞因子风暴和相关的肺损伤
Zhuojun Yu1, Yi Li1, Liping Bai2
1Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
International immunopharmacology
|October 25, 2024
概括
DBDx是一种三重药物组合,在细胞因子风暴的小鼠模型中显著改善了生存率. 这种治疗有效地减少了炎症性细胞因子和肺损伤,提供了一个有前途的治疗选择.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 病理学 病理学 病理学
背景情况:
- 细胞因子风暴是一种严重的,危及生命的疾病,需要有效的治疗.
- 目前对细胞因子风暴的治疗选择有限.
研究的目的:
- 为了研究DBDx的抗细胞因子风暴疗效,DBDx是一种三重药物组合:二皮里达摩尔,乌贝尼迈克斯和德克萨米他.
- 评估DBDx在脂聚糖 (LPS) 诱导的细胞因子风暴小鼠模型中的治疗潜力.
主要方法:
- 脂聚糖 (LPS) 诱导的细胞因子风暴小鼠模型.
- 与酶相关的免疫吸收试验 (ELISA) 和用于细胞因子量化的Luminex试验.
- 肺组织的组织病理学和超结构分析.
- 在体外实验中使用THP-1细胞评估TLR4/NF-κB/HIF-1α信号通路.
主要成果:
- 在小鼠模型中,DBDx显著提高了生存率和延长了生存时间.
- DBDx显著降低了TNF-α,IL-6和IL-1β的血清水平,以及广泛的炎症性细胞因子和化学因子.
- 组织病理学揭示了肺部损伤的减少,包括胀和中性粒细胞透的减少.
- 在体外研究表明,DBDx抑制了IL-6和TNF-α分泌,并降低了TLR4/NF-κB/HIF-1α通路的调节.
结论:
- DBDx显示出强大的抗细胞因子风暴疗效,超过了单个药物成分.
- DBDx通过抑制炎症通路来缓解细胞因子风暴诱导的肺损伤.
- 这种三重药物组合代表了对细胞因子风暴疾病的有希望的治疗策略.
相关概念视频
01:29Acute Respiratory Failure-V
124
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
124
01:26Flail Chest-II
160
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Assessment:
1. Clinical Evaluation:
History:
160
01:17Drugs Used in Lower Respiratory Disorders: Overview
353
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
353
01:26COPD: Management Using Bronchodilators and Corticosteroids
182
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
182